Format

Send to

Choose Destination
Kidney Int Rep. 2017 Sep 21;2(6):1018-1031. doi: 10.1016/j.ekir.2017.09.008. eCollection 2017 Nov.

The European Vasculitis Society 2016 Meeting Report.

Author information

1
Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
2
Guy's Hospital, London, UK.
3
Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
4
Medius Klinik Kirchheim/Vaskulitiszentrum Süd Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Tübingen, Germany.
5
Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
6
IZZ Immunologie-Zentrum Zürich, Zurich, Switzerland.
7
Trinity Health Kidney Centre, Tallaght Hospital, Dublin, Ireland.
8
Rheumatology Department, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK.
9
Hôpital Cochin, Paris, France.
10
Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, and Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
11
UCL Centre for Nephrology, Royal Free Hospital, London, UK.
12
Department of Medical and Health Sciences and Department of Nephrology, Linköping University, Linköping, Sweden.
13
Asia International Institute of Infectious Disease Control, Teikyo University, Tokyo, Japan.
14
Raigmore Hospital, Inverness, University of Aberdeen, Aberdeen, UK.
15
Clinic for Lupus, Vasculitis and Complement-mediated diseases, Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands.
16
Nephrology Unit, University Hospital, Parma, Italy.
17
Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Nephrology, Lund, Sweden.
18
Department of Medicine, University of Cambridge, Cambridge, UK.

Abstract

The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.

KEYWORDS:

ANCA; renal outcome; therapy; vasculitis

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center